Company intelligence / Profile preview
XtRNA Bio
- Ownership
- Private
- Development stage
- Preclinical
Overview
XtRNA Bio is a pioneering biotechnology company focused on developing transfer RNA (tRNA) therapeutics to treat rare genetic diseases, with a primary focus on Charcot-Marie-Tooth (CMT) disease. Co-founded by Professor Erik Storkebaum and NLC Health Ventures as a spin-out from Radboud University, the company leverages a dual-modality tRNA platform that enables both tRNA elevation and suppression therapies. Its lead program is a preclinical-stage viral gene therapy (AAV9-tRNAGly) designed to treat Charcot-Marie-Tooth disease type 2D (CMT2D) by restoring the cellular tRNA pool and rebalancing protein translation. Backed by funding from the CMT Research Foundation and NLC Health Ventures, XtRNA Bio aims to expand its platform to address other forms of CMT and genetic disorders caused by premature stop codons.
- Therapeutic areas
- Rare Diseases
- Modalities
- Gene therapyRNA therapyBiologic
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Sources
- Other public source
- Other public source
- Other public source
- Other public source
- Other public source
- Other public source
- Other public source
Full sources are available to Gosset users. Log in to see them.
Beyond the preview
Go deeper on XtRNA Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XtRNA Bio.
Work at XtRNA Bio? Claim this page to correct or add information. Claim this page